Geode Capital Management
BCTX

Geode Capital Management’s Briacell Therapeutics BCTX Stock Holding History

Geode Capital Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-269
Closed -$326K – 4980
2021
Q3 		$326K Buy
+269
New +$247K ﹤0.01% 4230

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
STA
Summit Trail Advisors New York $7.95B AUM 26.49% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return

Geode Capital Management's BCTX Position: Q4 2021 in Review

Geode Capital Management sold out of Briacell Therapeutics (BCTX) in Q4 2021, closing a stake of 269 shares — an estimated $326K sold.

Geode Capital Management first reported a position in BCTX in Q3 2021 and held it in 1 quarter. The position peaked at $326K in Q3 2021. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2021.

  • Geode Capital Management reported no remaining Briacell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Geode Capital Management sold 269 Briacell Therapeutics shares in Q4 2021, an estimated $326K.
  • Geode Capital Management first reported a position in Briacell Therapeutics in Q3 2021 and held it in 1 quarter.
  • Geode Capital Management's Briacell Therapeutics position peaked at $326K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2021.

Based on Geode Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.